| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -18.9 | -26.9 |
| Net income | -18.9 | -26.9 |
| EPS (diluted, $ a share) | $-1.76 | $-4.72 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ACET. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Adicet Bio, Inc.: key numbers
- Share price
- $2.75Close, Nov 16
- Market cap
- $25.7M
- Shares outstanding
- 9.36MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Adicet Bio, Inc.
All →Adicet Bio Leadership Change
Dr. Andrew Sinclair resigned from the Board of Directors and its committees effective November 13, 2026, with the board size subsequently reduced from seven to six members. Following the resignation, current director Michael Grissinger was appointed to the Audit Committee and named chairperson of the Nominating and Corporate Governance Committee. The company stated the resignation was not due to any disagreements regarding operations, policies, or practices.
Adicet Bio Financial Results
Adicet Bio reported third quarter 2026 financial results and provided updates on its clinical pipeline, including positive Phase 1 data for prula-cel in systemic lupus erythematosus. The company ended the quarter with $204.4 million in cash and cash equivalents, providing a projected runway into the second half of 2027.
- Term
- Q3 2026
“The growing body of evidence for prula-cel continues to strengthen our conviction in its potential to generate meaningful, lasting remissions for patients living with SLE, including those with LN and extra renal SLE. The compelling efficacy observed following complete discontinuation of immunosuppressants, together with evidence of a deep immune reset and a favorable safety profile supporting outpatient administration, reinforce the potential for prula-cel to meaningfully change the treatment paradigm for lupus patients.”
Chen Schor, President and Chief Executive Officer of Adicet Bio
Adicet Bio Clinical Trial Data
Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.
- Earnings call
- Sep 28, 2026, 8:00 AM ET